1. Godman B , Oortwijn W , De Waure C , et al. Links between pharmaceutical R&D models and access to affordable medicines. European Parliament. Directorate General for Internal Policies. Policy Department A: Economic and scientific Policy. European Union, PE 587.321 EN. IP/A/ENVI/2015-06, October 2016. http://www.europarl.europa.eu/thinktank/en/document.html?reference=IPOL_STU(2016)587321 (accessed March 14, 2017).
2. Wahlster P , Brereton L , Burns J , et al. Guidance on the integrated assessment of complex health technologies – The INTEGRATE-HTA Model [Online]. http://www.integrate-hta.eu/downloads/ (accessed March 14, 2017).
3. Health Technology Assessment international. Global Policy Forum. http://www.htai.org/policy-forum/global-policy-forum.html (accessed March 21, 2017).
4. World Health Organization, Health intervention and technology assessment in support of universal health coverage. Sixty-seventh World Health Assembly. WHA67.23 Ninth plenary meeting, May 24, 2014 A67/VR/9. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R23-en.pdf?ua=1 (accessed April 10, 2017).